|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
46,780,000 |
Market
Cap: |
87.48(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.32 - $3.73 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing precision therapies targeted to rare mutation-driven diseases. Co.'s primary drug product, FYARRO, is nab-sirolimus (sirolimus protein-bound particles for injectable suspension (albumin-bound)) for diseases driven by the mTOR pathway activation through mutations or deletions of specific genes such as Tuberous Sclerosis Complex 1 and 2. FYARRO is licensed to Co. by Abraxis BioScience, LLC, a wholly owned subsidiary of Bristol Myers Squibb Company, for various therapeutic areas including oncology, cardiovascular, and metabolic related diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
10,643 |
140,332 |
638,332 |
Total Sell Value |
$0 |
$25,011 |
$226,696 |
$2,016,128 |
Total People Sold |
0 |
3 |
4 |
4 |
Total Sell Transactions |
0 |
3 |
10 |
35 |
End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Dalal Anupam |
|
|
2025-03-04 |
4 |
A |
$2.40 |
$3,746,400 |
I/I |
1,561,000 |
3,410,402 |
|
- |
|
Zhao Baiteng |
|
|
2025-03-04 |
4 |
A |
$2.40 |
$3,000,000 |
I/I |
1,250,000 |
1,250,000 |
|
- |
|
Castelein Caley |
|
|
2025-03-04 |
4 |
A |
$2.40 |
$3,998,400 |
I/I |
1,666,000 |
2,165,998 |
|
- |
|
Ball Bryan |
See remarks |
|
2025-03-04 |
4 |
A |
$2.40 |
$240,000 |
D/D |
100,000 |
202,853 |
|
- |
|
Ball Bryan |
See remarks |
|
2025-03-03 |
4 |
S |
$2.35 |
$5,045 |
D/D |
(2,147) |
102,853 |
|
16% |
|
Giacobello Scott M. |
CHIEF FINANCIAL OFFICER |
|
2025-03-03 |
4 |
S |
$2.35 |
$6,594 |
D/D |
(2,806) |
23,944 |
|
16% |
|
Lennon David James |
CHIEF EXECUTIVE OFFICER |
|
2025-03-03 |
4 |
S |
$2.35 |
$13,372 |
D/D |
(5,690) |
33,429 |
|
16% |
|
Ball Bryan |
See remarks |
|
2025-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
105,000 |
|
- |
|
Giacobello Scott M. |
CHIEF FINANCIAL OFFICER |
|
2025-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,750 |
26,750 |
|
- |
|
Lennon David James |
CHIEF EXECUTIVE OFFICER |
|
2025-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,250 |
39,119 |
|
- |
|
Lennon David James |
CHIEF EXECUTIVE OFFICER |
|
2024-10-03 |
4 |
S |
$1.94 |
$18,797 |
D/D |
(9,689) |
22,869 |
|
-36% |
|
Lennon David James |
CHIEF EXECUTIVE OFFICER |
|
2024-10-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,558 |
32,558 |
|
- |
|
Desai Neil |
EXECUTIVE CHAIRMAN |
|
2024-09-03 |
4 |
AS |
$1.71 |
$68,316 |
I/I |
(40,000) |
1,171,543 |
|
67% |
|
Desai Neil |
EXECUTIVE CHAIRMAN |
|
2024-08-05 |
4 |
AS |
$1.34 |
$7,595 |
I/I |
(5,652) |
1,211,543 |
|
75% |
|
Desai Neil |
EXECUTIVE CHAIRMAN |
|
2024-08-02 |
4 |
AS |
$1.41 |
$26,705 |
I/I |
(18,933) |
1,217,195 |
|
73% |
|
Desai Neil |
EXECUTIVE CHAIRMAN |
|
2024-08-01 |
4 |
AS |
$1.50 |
$23,055 |
I/I |
(15,415) |
1,236,128 |
|
57% |
|
Desai Neil |
EXECUTIVE CHAIRMAN |
|
2024-07-02 |
4 |
AS |
$1.34 |
$11,612 |
I/I |
(8,652) |
1,251,543 |
|
61% |
|
Desai Neil |
EXECUTIVE CHAIRMAN |
|
2024-07-01 |
4 |
AS |
$1.45 |
$45,605 |
I/I |
(31,348) |
1,260,195 |
|
48% |
|
Desai Neil |
EXECUTIVE CHAIRMAN |
|
2024-06-04 |
4 |
AS |
$1.77 |
$35,746 |
I/I |
(20,225) |
1,291,543 |
|
22% |
|
Desai Neil |
EXECUTIVE CHAIRMAN |
|
2024-06-03 |
4 |
AS |
$1.81 |
$35,765 |
I/I |
(19,775) |
1,311,768 |
|
13% |
|
Desai Neil |
EXECUTIVE CHAIRMAN |
|
2024-05-01 |
4 |
AS |
$1.93 |
$77,184 |
I/I |
(40,000) |
1,331,543 |
|
-5% |
|
Ball Bryan |
See remarks |
|
2024-04-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
100,000 |
|
-2% |
|
Desai Neil |
EXECUTIVE CHAIRMAN |
|
2024-04-02 |
4 |
AS |
$2.23 |
$49,513 |
I/I |
(22,228) |
1,371,543 |
|
-36% |
|
Desai Neil |
EXECUTIVE CHAIRMAN |
|
2024-04-01 |
4 |
AS |
$2.31 |
$41,101 |
I/I |
(17,772) |
1,393,771 |
|
-40% |
|
Desai Neil |
EXECUTIVE CHAIRMAN |
|
2024-03-04 |
4 |
AS |
$2.10 |
$31,415 |
I/I |
(14,964) |
1,411,543 |
|
-39% |
|
159 Records found
|
|
Page 1 of 7 |
|
|